Medicinehospital

Recombinant Coagulation Factor VIII Single Chain

Clotting factor replacement for haemophilia A.

Clinical information

Common uses

treating and controlling bleeding episodes
routine prevention of bleeding
managing bleeding around surgery

Common side effects

dizziness
hypersensitivity reactions
factor VIII inhibitors in previously untreated patients

Cautions

allergic reactions, including anaphylaxis, possible
the body can develop antibodies that stop it working
not for von Willebrand disease
contains hamster protein traces — allergy risk

Pregnancy: no data — discuss with your doctor

Reference information, not medical advice — always follow your doctor or pharmacist. Source: DailyMed, dailymed.nlm.nih.gov, Afstyla (antihemophilic factor, recombinant, single chain) label, setid 51f19873-a63f-4229-9477-5da4ecf31cde (accessed 2026-08-16)

Approved brands & formulations2

Brand name	Dosage form	Strength	Importer	Category
Afstyla	Parenteral ( Injection )	500 IU	authorized importers after registration of the product	hospital
Afstyla	Parenteral ( Injection )	3000 IU	authorized importers after registration of the product	hospital